{"id":515483,"date":"2021-07-21T06:33:07","date_gmt":"2021-07-21T10:33:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-began-generating-contract-medical-device-rd-revenue\/"},"modified":"2021-07-21T06:33:07","modified_gmt":"2021-07-21T10:33:07","slug":"anpac-bio-began-generating-contract-medical-device-rd-revenue","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-began-generating-contract-medical-device-rd-revenue\/","title":{"rendered":"AnPac Bio Began Generating Contract Medical Device R&D Revenue"},"content":{"rendered":"

\nAlso in Final Stages of Partnership\/Cooperation Discussions with Major Corporations
\n<\/h2>\n
\n

PHILADELPHIA, July 21, 2021 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (\u201cAnPac Bio,\u201d the \u201cCompany\u201d or \u201cwe\u201d) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that it had entered into an agreement with Advanced Life Therapeutics Co., Ltd. (\u201cAdvanced Life Therapeutics\u201d), in which the Company holds a minority equity interest of 40%, to perform contract R&D on integrated circuit-based components for cancer treatment medical devices. Under the multi-year contract agreement, the Company will design, fabricate, test and optimize key components of a cancer treatment medical device. The Company expects to begin generating revenue from this contract R&D project starting Q3 of this year.<\/p>\n

The Company is also in later stages of partnership\/cooperation discussions with a number of major corporations in the medical industry, in order to (a) increase the Company\u2019s commercial Cancer Differentiation Analysis (CDA)-based cancer test revenue, and (b) broaden the Company\u2019s new product pipeline in which the Company and its partner(s) will jointly develop medical devices which will leverage AnPac Bio\u2019s strong expertise in integrated circuit (IC) based core components in medical devices.<\/p>\n

Anpac Bio\u2019s CEO, Dr. Chris Yu remarked of this progress, \u201cWe are pleased to initiate our first contract medical device R&D to bring additional revenue streams to our company. We also look forward to finalizing the pending major partnerships\/cooperation to increase our core cancer screening and detection test revenue, and broaden our product pipeline.\u201d \u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n

\n About AnPac Bio<\/strong>\n <\/p>\n

AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 142 issued patents as of March 31, 2021. With two certified clinical laboratories in China and one CLIA and CAP accredited clinical laboratory and one CLIA registered clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics tests. According to Frost & Sullivan, AnPac Bio ranked third worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection, based on approximately 41,700 clinical samples as of December 31, 2019. AnPac Bio\u2019s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity.<\/p>\n

For more information, please visit:\u00a0https:\/\/www.Anpacbio.com<\/a><\/u>.<\/p>\n

\n For investor and media inquiries, please contact:<\/strong>\n <\/p>\n

\n Company:<\/em>
\n
Phil Case, Marketing and Investor Relations
Phone: +1-267-810-6776 (US)
Email:\u00a0phil_case@AnPacbio.com<\/a><\/u><\/p>\n

\n Investor Relations:<\/em>
\n
Ascent Investor Relations LLC
Tina Xiao, President
Phone: +1-917-609-0333 (US)
Email:\u00a0tina.xiao@ascent-ir.com<\/a><\/u><\/p>\n

\n Safe Harbor Statement<\/strong>\n <\/p>\n

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made under the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company\u2019s future financial and operating performance. The Company has attempted to identify forward-looking statements by terminologies including \u201cbelieves,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cprojects,\u201d \u201cintends,\u201d \u201cpotential,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cpredict,\u201d \u201coutlook,\u201d \u201cseek,\u201d \u201cgoal\u201d \u201cobjective,\u201d \u201cassume,\u201d \u201ccontemplate,\u201d \u201ccontinue,\u201d \u201cpositioned,\u201d \u201cforecast,\u201d \u201clikely,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201capproximately\u201d or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company\u2019s control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company\u2019s actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, the implementation of our business model and growth strategies; trends and competition in the cancer screening and detection market; our expectations regarding demand for and market acceptance of our cancer screening and detection tests and our ability to expand our customer base; our ability to obtain and maintain intellectual property protections for our CDA technology and our continued research and development to keep pace with technology developments; our ability to obtain and maintain regulatory approvals from the NMPA, the FDA and the relevant U.S. states and have our laboratories certified or accredited by authorities including the CLIA; our future business development, financial condition and results of operations and our ability to obtain financing cost-effectively; potential changes of government regulations; general economic and business conditions in China and elsewhere; our ability to hire and maintain key personnel; our relationship with our major business partners and customers; and the duration of the coronavirus outbreaks and their potential adverse impact on the economic conditions and financial markets and our business and financial performance, such as resulting from reduced commercial activities due to quarantines and travel restrictions instituted by China, the U.S. and many other countries around the world to contain the spread of the virus. Additionally, all forward-looking statements are subject to the \u201cRisk Factors\u201d detailed from time to time in the Company\u2019s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.<\/p>\n<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Also in Final Stages of Partnership\/Cooperation Discussions with Major Corporations PHILADELPHIA, July 21, 2021 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (\u201cAnPac Bio,\u201d the \u201cCompany\u201d or \u201cwe\u201d) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that it had entered into an agreement with Advanced Life Therapeutics Co., Ltd. (\u201cAdvanced Life Therapeutics\u201d), in which the Company holds a minority equity interest of 40%, to perform contract R&D on integrated circuit-based components for cancer treatment medical devices. Under the multi-year contract agreement, the Company will design, fabricate, test and optimize key components of a cancer treatment medical device. The Company expects to begin generating revenue from this … <\/p>\n

Continue reading “AnPac Bio Began Generating Contract Medical Device R&D Revenue”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-515483","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAnPac Bio Began Generating Contract Medical Device R&D Revenue - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-began-generating-contract-medical-device-rd-revenue\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AnPac Bio Began Generating Contract Medical Device R&D Revenue - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Also in Final Stages of Partnership\/Cooperation Discussions with Major Corporations PHILADELPHIA, July 21, 2021 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (\u201cAnPac Bio,\u201d the \u201cCompany\u201d or \u201cwe\u201d) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that it had entered into an agreement with Advanced Life Therapeutics Co., Ltd. (\u201cAdvanced Life Therapeutics\u201d), in which the Company holds a minority equity interest of 40%, to perform contract R&D on integrated circuit-based components for cancer treatment medical devices. Under the multi-year contract agreement, the Company will design, fabricate, test and optimize key components of a cancer treatment medical device. The Company expects to begin generating revenue from this … Continue reading "AnPac Bio Began Generating Contract Medical Device R&D Revenue"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-began-generating-contract-medical-device-rd-revenue\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-21T10:33:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDAwNyM0MzA3MTY5IzIxOTM2OTQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-began-generating-contract-medical-device-rd-revenue\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-began-generating-contract-medical-device-rd-revenue\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AnPac Bio Began Generating Contract Medical Device R&D Revenue\",\"datePublished\":\"2021-07-21T10:33:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-began-generating-contract-medical-device-rd-revenue\\\/\"},\"wordCount\":968,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-began-generating-contract-medical-device-rd-revenue\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NDAwNyM0MzA3MTY5IzIxOTM2OTQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-began-generating-contract-medical-device-rd-revenue\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-began-generating-contract-medical-device-rd-revenue\\\/\",\"name\":\"AnPac Bio Began Generating Contract Medical Device R&D Revenue - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-began-generating-contract-medical-device-rd-revenue\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-began-generating-contract-medical-device-rd-revenue\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NDAwNyM0MzA3MTY5IzIxOTM2OTQ=\",\"datePublished\":\"2021-07-21T10:33:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-began-generating-contract-medical-device-rd-revenue\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-began-generating-contract-medical-device-rd-revenue\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-began-generating-contract-medical-device-rd-revenue\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NDAwNyM0MzA3MTY5IzIxOTM2OTQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NDAwNyM0MzA3MTY5IzIxOTM2OTQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anpac-bio-began-generating-contract-medical-device-rd-revenue\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AnPac Bio Began Generating Contract Medical Device R&D Revenue\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AnPac Bio Began Generating Contract Medical Device R&D Revenue - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-began-generating-contract-medical-device-rd-revenue\/","og_locale":"en_US","og_type":"article","og_title":"AnPac Bio Began Generating Contract Medical Device R&D Revenue - Market Newsdesk","og_description":"Also in Final Stages of Partnership\/Cooperation Discussions with Major Corporations PHILADELPHIA, July 21, 2021 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (\u201cAnPac Bio,\u201d the \u201cCompany\u201d or \u201cwe\u201d) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that it had entered into an agreement with Advanced Life Therapeutics Co., Ltd. (\u201cAdvanced Life Therapeutics\u201d), in which the Company holds a minority equity interest of 40%, to perform contract R&D on integrated circuit-based components for cancer treatment medical devices. Under the multi-year contract agreement, the Company will design, fabricate, test and optimize key components of a cancer treatment medical device. The Company expects to begin generating revenue from this … Continue reading \"AnPac Bio Began Generating Contract Medical Device R&D Revenue\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-began-generating-contract-medical-device-rd-revenue\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-21T10:33:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDAwNyM0MzA3MTY5IzIxOTM2OTQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-began-generating-contract-medical-device-rd-revenue\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-began-generating-contract-medical-device-rd-revenue\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AnPac Bio Began Generating Contract Medical Device R&D Revenue","datePublished":"2021-07-21T10:33:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-began-generating-contract-medical-device-rd-revenue\/"},"wordCount":968,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-began-generating-contract-medical-device-rd-revenue\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDAwNyM0MzA3MTY5IzIxOTM2OTQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-began-generating-contract-medical-device-rd-revenue\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-began-generating-contract-medical-device-rd-revenue\/","name":"AnPac Bio Began Generating Contract Medical Device R&D Revenue - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-began-generating-contract-medical-device-rd-revenue\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-began-generating-contract-medical-device-rd-revenue\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDAwNyM0MzA3MTY5IzIxOTM2OTQ=","datePublished":"2021-07-21T10:33:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-began-generating-contract-medical-device-rd-revenue\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-began-generating-contract-medical-device-rd-revenue\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-began-generating-contract-medical-device-rd-revenue\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDAwNyM0MzA3MTY5IzIxOTM2OTQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDAwNyM0MzA3MTY5IzIxOTM2OTQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anpac-bio-began-generating-contract-medical-device-rd-revenue\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AnPac Bio Began Generating Contract Medical Device R&D Revenue"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/515483","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=515483"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/515483\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=515483"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=515483"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=515483"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}